Relapsed/Refractory Multiple Myeloma: Practice Pearls and Future Directions in Care
Thomas Martin, MD; Ajay Nooka, MD; and Jeremy Larsen, MD, share closing thoughts on the evolving landscape of cytokine release syndrome management in relapsed/refractory multiple myeloma.
Real-World Management of CRS in Patients With Relapsed/Refractory Multiple Myeloma
Following their review of data from MajesTEC-1, panelists consider how they manage patients with cytokine release syndrome in the real-world setting.
Management of CRS in MajesTEC-1: Role of Tocilizumab in RRMM
Key opinion leaders Thomas Martin, MD; Ajay Nooka, MD; and Jeremy Larsen, MD, reflect on the use of tocilizumab in patients experiencing cytokine release syndrome on MajesTEC-1.
Relapsed/Refractory Multiple Myeloma: Incidence of CRS in MajesTEC-1
Focused discussion on the advent of cytokine release syndrome in MajesTEC-1 and how it compared to the benefits derived from teclistamab therapy.
Relapsed/Refractory Multiple Myeloma: Factors in Selecting Later-Line Therapy
Experts on multiple myeloma discuss how to select treatment options in later lines of therapy.
Overview of Treatment Options for Relapsed/Refractory Multiple Myeloma
Key opinion leaders share comprehensive insight to the treatment armamentarium for patients with relapsed/refractory multiple myeloma.
Overview of Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma
Experts Thomas Martin, MD; Ajay Nooka, MD; and Jeremy Larsen, MD, provide a broad overview of cytokine release syndrome as it relates to the management of multiple myeloma.
Thomas Martin, MD, on Excitement for a Cilta-Cel Approval in R/R Multiple Myeloma
Thomas Martin, MD, spoke about how the approval of ciltacabtagene autoleucel for patients with relapsed/refractory multiple myeloma may change the standard of care in this setting.
Thomas Martin, MD, on Moving Forward With Cilta-Cel Treatment in Multiple Myeloma
Thomas Martin, MD, spoke about how to increase response durability with ciltacabtagene autoleucel for patients with heavily pretreated multiple myeloma.
Thomas Martin, MD, on the Benefits of Cilta-Cel in R/R Multiple Myeloma
Thomas Martin, MD, spoke about which patient population with relapsed/refractory multiple myeloma would benefit most from treatment with ciltacabtagene autoleucel.
Thomas Martin, MD, Discusses Importance of Cilta-Cel Approval in Multiple Myeloma
Thomas Martin, MD, spoke about the importance of the approval of ciltacabtagene autoleucel to treat patients with pretreated multiple myeloma.
Thomas G. Martin, MD, Discusses Updated Results of CARTITUDE-1 at ASH 2021
Thomas G. Martin, MD, spoke about the updated results of the CARTITUDE-1 study examining ciltacabtagene autoleucel in relapsed or refractory multiple myeloma.
Thomas G. Martin, MD, on Results of CARTITUDE-1 and Other Data for Cilta-Cel at ASH 2021
Thomas G. Martin, MD, spoke about the previously reported results of the CARTITUDE-1 study in patients with relapsed or refractory myeloma ahead of the 2021 ASH Annual Meeting.
Thomas G. Martin, MD, Discusses Which Abstracts on BCMA Targeted Therapies He’s Excited to See at ASH 2021
Thomas G. Martin, MD, spoke about the abstracts regarding B-cell maturation antigen–targeted treatments he’s excited to see presented at ASH 2021.
Thomas G. Martin, MD, Discusses Abstracts He’s Eagerly Anticipating for Presentation at 2021 ASH
Thomas G. Martin, MD, spoke about different abstracts to be presented at ASH 2021.
Peripheral Neuropathy Experience in Patients With Relapsed and/or Refractory Multiple Myeloma Treated With Carfilzomib
The adverse event profile of single-agent carfilzomib suggests that the agent is an important treatment option for patients with advanced multiple myeloma, particularly those with pre-existing peripheral neuropathy or those who are at risk for the development of peripheral neuropathy.